MicroSectors FANG and Innovation 3X Leveraged ETN vs Hims and Hers Health Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.82 (market cap $2.98B), while Hims and Hers Health Inc trades at $30.92 (market cap $6.55B). The key difference: Hims and Hers Health Inc is far larger — about 2.2× MicroSectors FANG and Innovation 3X Leveraged ETN's market cap, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and Hims and Hers Health Inc for 21 Days on average.
| FNGU | HIMS | |
|---|---|---|
Market Cap | $2.98B | $6.55B |
Volume | 4,682,352 | 14,842,814 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $62.76 |
52-Week Low | $13.73 | $14.52 |
Typical Hold Time | 19 Days | 21 Days |
Enterprise Value | — | $7.25B |
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $36.82, down 1.02% today. Technical signals are bullish based on moving averages, with neutral oscillators suggesting potential consolidation. Support and resistance levels are tightly clustered between $33 and $39, indicating a critical price zone. Recent news highlights the ETN's high volatility, having lost 87% during past tech sector downturns, underscoring its leveraged risk profile.
The outlook for FNGU hinges on sustained strength in its underlying tech holdings like Nvidia and Apple. While bullish momentum offers upside potential, the extreme leverage amplifies risks during market corrections. Investors face significant volatility, with losses magnified in downturns, making it suitable only for those with high risk tolerance and short-term horizons.
Hims & Hers Health trades at $30.92, up 4.67% on the day, amid a bearish technical signal and significant legal headwinds from multiple securities class action lawsuits. The stock shows mixed fundamentals with strong revenue growth to $2.35 billion in 2025 but a sharp reversal to a net loss of -$142 million in 2026, reflecting profitability challenges. Valuation ratios appear elevated with a P/E of 57.14 and EV/EBITDA of 205.86, while analyst consensus remains cautiously optimistic with a $32.17 price target.
The outlook is clouded by legal risks and recent earnings misses, though the company's gross margin of 68.43% indicates underlying business strength. Investment opportunity hinges on resolving regulatory scrutiny and returning to profitability, but near-term volatility is likely. Key risks include the FTC lawsuit outcome and sustained negative cash flow, demanding careful risk assessment by investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →